Sanofi Canada has issued a press release announcing that the License and Development Agreement between Sanofi and kaléo, formerly Intelliject Inc., the developer of Auvi-Q® and Allerject® (epinephrine injection, USP) will terminate later this year.
To see the full release, click here where you will also find contact information for the company.
Special Note: Allerject® consumers were advised to have their devices replaced with EpiPens® following the national voluntary recall last year. Click here to see the company’s statement about the recall.
For your information,
Food Allergy Canada
Tags: Allerject